Transfusion reaction: Difference between revisions
Line 14: | Line 14: | ||
*Blood products can provide an excellent medium for [[bacteria]]l growth, and can become contaminated after collection while they are being stored. | *Blood products can provide an excellent medium for [[bacteria]]l growth, and can become contaminated after collection while they are being stored. | ||
*The risk is highest with [[platelet]] transfusion, since platelets must be stored near room temperature and cannot be refrigerated. | *The risk is highest with [[platelet]] transfusion, since platelets must be stored near room temperature and cannot be refrigerated. | ||
*The risk of severe bacterial infection and [[sepsis]] is estimated (as of 2001) at about 1 in 50,000 platelet transfusions, and 1 in 500,000 red blood cell transfusions. | *The risk of severe bacterial infection and [[sepsis]] is estimated (as of 2001) at about 1 in 50,000 platelet transfusions, and 1 in 500,000 red blood cell transfusions. | ||
===Acute Hemolytic Reaction=== | ===Acute Hemolytic Reaction=== | ||
*This is a [[medical emergency]] resulting from rapid destruction ([[hemolysis]]) of the donor red blood cells by host [[antibody|antibodies]]. | *This is a [[medical emergency]] resulting from rapid destruction ([[hemolysis]]) of the donor red blood cells by host [[antibody|antibodies]]. | ||
Line 25: | Line 25: | ||
===Transfusion-associated Acute Lung Injury (TRALI)=== | ===Transfusion-associated Acute Lung Injury (TRALI)=== | ||
*[[TRALI]] is a syndrome of acute [[respiratory distress]], often associated with [[fever]], non-cardiogenic [[pulmonary edema]], and [[hypotension]]. | *[[TRALI]] is a syndrome of acute [[respiratory distress]], often associated with [[fever]], non-cardiogenic [[pulmonary edema]], and [[hypotension]]. | ||
*It may occur as often as 1 in 2000 transfusions. | *It may occur as often as 1 in 2000 transfusions. | ||
*Symptoms can range from mild to life-threatening, but most patients recover fully within 96 hours, and the mortality rate from this condition is less than 10%. | *Symptoms can range from mild to life-threatening, but most patients recover fully within 96 hours, and the mortality rate from this condition is less than 10%. | ||
===Volume Overload=== | ===Volume Overload=== | ||
*Patients with impaired cardiac function (eg [[congestive heart failure]]) can become volume-overloaded as a result of blood transfusion, leading to [[edema]], [[dyspnea]] (shortness of breath), and [[orthopnea]] (shortness of breath while lying flat). *This is sometimes called TACO, or Transfusion Associated Circulatory Overload. | *Patients with impaired cardiac function (eg [[congestive heart failure]]) can become volume-overloaded as a result of blood transfusion, leading to [[edema]], [[dyspnea]] (shortness of breath), and [[orthopnea]] (shortness of breath while lying flat). *This is sometimes called TACO, or Transfusion Associated Circulatory Overload. | ||
Line 33: | Line 33: | ||
*Since elimination pathways for iron are limited, a person receiving numerous red blood cell transfusions can develop [[iron overload]], which can in turn damage the [[liver]], [[heart]], [[kidney]]s, and [[pancreas]]. The threshold at which iron overload becomes significant is somewhat unclear, but is likely around 12-20 units of red blood cells transfused. | *Since elimination pathways for iron are limited, a person receiving numerous red blood cell transfusions can develop [[iron overload]], which can in turn damage the [[liver]], [[heart]], [[kidney]]s, and [[pancreas]]. The threshold at which iron overload becomes significant is somewhat unclear, but is likely around 12-20 units of red blood cells transfused. | ||
===Transfusion-associated Graft-vs-Host Disease (GvHD)=== | ===Transfusion-associated Graft-vs-Host Disease (GvHD)=== | ||
*[[graft-versus-host disease|GVHD]] refers to an immune attack by transfused cells against the recipient. This is a common complication of [[stem cell transplant]]ation, but an exceedingly rare complication of blood transfusion. It occurs only in severely immunosuppressed patients, primarily those with [[congenital]] immune deficiencies or [[hematological malignancy|hematologic malignancies]] who are receiving intensive [[chemotherapy]]. When GVHD occurs in association with blood transfusion, it is almost uniformly fatal. | *[[graft-versus-host disease|GVHD]] refers to an immune attack by transfused cells against the recipient. This is a common complication of [[stem cell transplant]]ation, but an exceedingly rare complication of blood transfusion. It occurs only in severely immunosuppressed patients, primarily those with [[congenital]] immune deficiencies or [[hematological malignancy|hematologic malignancies]] who are receiving intensive [[chemotherapy]]. When GVHD occurs in association with blood transfusion, it is almost uniformly fatal. Transfusion-associated GVHD can be prevented by [[irradiation|irradiating]] the blood products prior to transfusion. | ||
===Transfusion-associated Microchimerism (TA-MC)=== | ===Transfusion-associated Microchimerism (TA-MC)=== | ||
*Transfusion-associated [[Chimera (genetics)#Microchimerism|microchimerism]] is the stable persistence of donor's genetically distinct cells (usually <5%) in a recipient's circulation following fresh [[blood transfusion]], especially in the setting of [[Physical trauma|trauma]]. | *Transfusion-associated [[Chimera (genetics)#Microchimerism|microchimerism]] is the stable persistence of donor's genetically distinct cells (usually <5%) in a recipient's circulation following fresh [[blood transfusion]], especially in the setting of [[Physical trauma|trauma]]. | ||
*As a result of the current advancement in [[polymerase chain reaction]] techniques, TA-MC has been demonstrated among patients with [[Physical trauma|trauma]] following [[blood transfusion]], [[pregnancy]] and [[transplant|organ or stem cell transplantation]]. Several studies have implicated other forms of [[Chimera (genetics)#Microchimerism|microchimerism]], including [[Chimera (genetics)|fetomaternal microchimerism]], with acute and chronic illnesses such as [[congenital heart block]] in a patient with [[neonatal lupus erythematosus]] | *As a result of the current advancement in [[polymerase chain reaction]] techniques, TA-MC has been demonstrated among patients with [[Physical trauma|trauma]] following [[blood transfusion]], [[pregnancy]] and [[transplant|organ or stem cell transplantation]]. Several studies have implicated other forms of [[Chimera (genetics)#Microchimerism|microchimerism]], including [[Chimera (genetics)|fetomaternal microchimerism]], with acute and chronic illnesses such as [[congenital heart block]] in a patient with [[neonatal lupus erythematosus]] and [[systemic sclerosis]]. | ||
Genetic factors such as the [[Tumor necrosis factors|TNF]] (-308A) [[single nucleotide polymorphism]]s (SNP) have been implicated in the development of TA-MC. The risk of developing TA-MC is largely dependent on the clinical setting, i.e., it is rare in situations which do not involve massive trauma. | Genetic factors such as the [[Tumor necrosis factors|TNF]] (-308A) [[single nucleotide polymorphism]]s (SNP) have been implicated in the development of TA-MC. The risk of developing TA-MC is largely dependent on the clinical setting, i.e., it is rare in situations which do not involve massive trauma. Although [[leukoreduction]] removes > 99.9% of donor's [[white blood cell]]s, it has not been proven to prevent the development of TA-MC. | ||
==Treatment of Transfusion Reactions== | ==Treatment of Transfusion Reactions== | ||
Line 46: | Line 46: | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" |Transfusion Reaction | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Transfusion Reaction | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" |Time of onset | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Time of onset | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" |Fever | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Fever | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" |Rigors | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Rigors | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" |Rash | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Rash | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" |Blood Pressure | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Blood Pressure | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" | | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Additional Features | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" | | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Labs | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" | | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Treatment | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" | | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Prevention | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" | | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Mechanism/ | ||
Examples | |||
|- | |- | ||
!style="padding: 5px 5px; background: #DCDCDC;" align="center" | | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Anaphylactic Reaction | ||
| | | | ||
* | * Rapid onset | ||
|<nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | | ||
* | * Hypotension | ||
| | | | ||
* | * Wheezing | ||
* | * stridor | ||
* cyanosis | |||
* soft tissue edema | |||
| | | | ||
* | * CBC | ||
* spO2 monitoring | |||
* type and screen | |||
| | | | ||
* | * Stop the transfusion immediately | ||
* | * S/C epinephrine | ||
* IV epinephrine(in case of severe hypotension) | |||
| | | | ||
* | * Avoid clerical errors | ||
* proper storage record | |||
* repeat type and screen before transfusion | |||
* proper blood storage conditions | |||
|[[IgA deficiency]] | |||
|- | |- | ||
!style="padding: 5px 5px; background: #DCDCDC;" align="center" |Bacterial Infection | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Bacterial Infection | ||
| | | | ||
* Rapid onset | * Rapid onset | ||
Line 87: | Line 96: | ||
* Hypotension is common | * Hypotension is common | ||
* occasionally hypertension | * occasionally hypertension | ||
| | | | ||
* fever > 2 | * fever > 2 | ||
Line 109: | Line 117: | ||
* leukodepletion | * leukodepletion | ||
* bactericidal treatment | * bactericidal treatment | ||
| +/- | |||
|- | |- | ||
!style="padding: 5px 5px; background: #DCDCDC;" align="center" |Acute Hemolytic Reaction | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Acute Hemolytic Reaction | ||
| | | | ||
* Rapid onet | * Rapid onet | ||
Line 118: | Line 127: | ||
| | | | ||
* Hypotension | * Hypotension | ||
| | | | ||
* Chest pain | * Chest pain | ||
* apprehension | * apprehension | ||
* flank pain | * flank pain | ||
* dark urine | * dark urine([[Hemoglobinura]]) | ||
* [[Renal failure]] | |||
* oozing from venipuncture site ( DIC) | * oozing from venipuncture site ( DIC) | ||
| | | | ||
Line 132: | Line 141: | ||
* Serum LDL | * Serum LDL | ||
* Serum bilirubin | * Serum bilirubin | ||
* | * [[Prothrombin time]] | ||
* | * [[Coomb's test]]=+ve | ||
| | | | ||
* Stop the transfusion immediately | * Stop the transfusion immediately | ||
Line 147: | Line 156: | ||
* repeat type and screen before transfusion | * repeat type and screen before transfusion | ||
* proper blood storage conditions | * proper blood storage conditions | ||
|[[ABO incompatibility (patient information)|ABO incompatibility]] | |||
|- | |- | ||
!style="padding: 5px 5px; background: #DCDCDC;" align="center" | | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Febrile Non-hemolytic Transfusion Reaction | ||
| | | | ||
* | * 1/2 to 1 hour | ||
| | | +, with chills | ||
|<nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | | ||
* | * No Effect | ||
| | | | ||
* | * can occur in first few hours | ||
* | * fever rise of 1-2 | ||
| | | | ||
* | * No labs usually required | ||
| | | | ||
* Stop the transfusion | * Slow or Stop the transfusion | ||
* | * Give Acetaminophen for fever | ||
| | | | ||
* | * Leukoreduction | ||
|Cytokine in storage | |||
|- | |- | ||
!style="padding: 5px 5px; background: #DCDCDC;" align="center" |Transfusion-related acute lung injury (TRALI) | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Transfusion-related acute lung injury (TRALI) | ||
|within 6 hours | |within 6 hours | ||
| +/- | | +/- | ||
Line 183: | Line 185: | ||
| | | | ||
* Hypotension | * Hypotension | ||
| | | | ||
* cough | * cough | ||
* pink frothy sputum | * pink frothy sputum | ||
* [[Respiratory distress]] | |||
* [[Pulmonary edema]] | |||
| | | | ||
* ABGs | * ABGs | ||
Line 203: | Line 206: | ||
| | | | ||
* donor whose blood cause TRALI must be put on non-donor list | * donor whose blood cause TRALI must be put on non-donor list | ||
| Donor anti-leukocyte antibodies | |||
|- | |- | ||
!style="padding: 5px 5px; background: #DCDCDC;" align="center" |Transfusion-associated circulatory overload (TACO) | ! style="padding: 5px 5px; background: #DCDCDC;" align="center" |Transfusion-associated circulatory overload (TACO) | ||
|usually over hours | |usually over hours | ||
| - | | - | ||
Line 211: | Line 215: | ||
| | | | ||
* Hypertension | * Hypertension | ||
| | | | ||
* dyspnea | * dyspnea | ||
Line 238: | Line 241: | ||
* avoid unnecessary transfusion | * avoid unnecessary transfusion | ||
* cardiac evluation | * cardiac evluation | ||
| +++ | |||
|} | |} | ||
Line 243: | Line 247: | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" |Parameters | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Parameters | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" |Transfusion-related acute lung injury (TRALI) | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Transfusion-related acute lung injury (TRALI) | ||
!style="background:#4479BA; color: #FFFFFF;" align="center" |Transfusion-associated circulatory overload (TACO) | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Transfusion-associated circulatory overload (TACO) | ||
|- | |- | ||
|Fever | |Fever |
Revision as of 17:56, 5 September 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Overview
Types of Transfusion Reactions
Febrile Non-hemolytic Transfusion Reaction
- This is the most common adverse reaction to a blood transfusion.
- Symptoms include fever and dyspnea 1 to 6 hours after receiving the transfusion.
- Such reactions are clinically benign, causing no lasting side effects or problems, but are unpleasant via a blood transfusion is estimated, as of 2006, at 1 per 2 million units transfused. Bacterial infection is a much more common problem.
Bacterial Infection
- Blood products can provide an excellent medium for bacterial growth, and can become contaminated after collection while they are being stored.
- The risk is highest with platelet transfusion, since platelets must be stored near room temperature and cannot be refrigerated.
- The risk of severe bacterial infection and sepsis is estimated (as of 2001) at about 1 in 50,000 platelet transfusions, and 1 in 500,000 red blood cell transfusions.
Acute Hemolytic Reaction
- This is a medical emergency resulting from rapid destruction (hemolysis) of the donor red blood cells by host antibodies.
- The most common cause is clerical error (i.e. the wrong unit of blood being given to the wrong patient).
- The symptoms are fever and chills, sometimes with back pain and pink or red urine (hemoglobinuria).
- The major complication is that hemoglobin released by the destruction of red blood cells can cause acute renal failure.
Anaphylactic Reaction
- An anaphylactic (or severe allergic) reaction can occur at a rate of 1 per 30,000-50,000 transfusions.
- These reactions are most common in people with selective IgA deficiency (although IgA deficiency is often asymptomatic, and people may not know they have it until an anaphylactic reaction occurs).
Transfusion-associated Acute Lung Injury (TRALI)
- TRALI is a syndrome of acute respiratory distress, often associated with fever, non-cardiogenic pulmonary edema, and hypotension.
- It may occur as often as 1 in 2000 transfusions.
- Symptoms can range from mild to life-threatening, but most patients recover fully within 96 hours, and the mortality rate from this condition is less than 10%.
Volume Overload
- Patients with impaired cardiac function (eg congestive heart failure) can become volume-overloaded as a result of blood transfusion, leading to edema, dyspnea (shortness of breath), and orthopnea (shortness of breath while lying flat). *This is sometimes called TACO, or Transfusion Associated Circulatory Overload.
Iron overload
- Each transfused unit of red blood cells contains approximately 250 mg of elemental iron.
- Since elimination pathways for iron are limited, a person receiving numerous red blood cell transfusions can develop iron overload, which can in turn damage the liver, heart, kidneys, and pancreas. The threshold at which iron overload becomes significant is somewhat unclear, but is likely around 12-20 units of red blood cells transfused.
Transfusion-associated Graft-vs-Host Disease (GvHD)
- GVHD refers to an immune attack by transfused cells against the recipient. This is a common complication of stem cell transplantation, but an exceedingly rare complication of blood transfusion. It occurs only in severely immunosuppressed patients, primarily those with congenital immune deficiencies or hematologic malignancies who are receiving intensive chemotherapy. When GVHD occurs in association with blood transfusion, it is almost uniformly fatal. Transfusion-associated GVHD can be prevented by irradiating the blood products prior to transfusion.
Transfusion-associated Microchimerism (TA-MC)
- Transfusion-associated microchimerism is the stable persistence of donor's genetically distinct cells (usually <5%) in a recipient's circulation following fresh blood transfusion, especially in the setting of trauma.
- As a result of the current advancement in polymerase chain reaction techniques, TA-MC has been demonstrated among patients with trauma following blood transfusion, pregnancy and organ or stem cell transplantation. Several studies have implicated other forms of microchimerism, including fetomaternal microchimerism, with acute and chronic illnesses such as congenital heart block in a patient with neonatal lupus erythematosus and systemic sclerosis.
Genetic factors such as the TNF (-308A) single nucleotide polymorphisms (SNP) have been implicated in the development of TA-MC. The risk of developing TA-MC is largely dependent on the clinical setting, i.e., it is rare in situations which do not involve massive trauma. Although leukoreduction removes > 99.9% of donor's white blood cells, it has not been proven to prevent the development of TA-MC.
Treatment of Transfusion Reactions
The most important step in treating a presumed transfusion reaction is to stop the transfusion immediately (saving the remaining blood and IV tubing for testing) and to provide supportive care to the patient. More specific treatments depend on the nature and presumed cause of the transfusion reaction. Most hospitals and medical centers have transfusion reaction protocols, which specify testing of the blood product and patient for hemolysis, bacterial contamination, etc.
The following table shows different types of transfusion reactions along with their treatment,
Transfusion Reaction | Time of onset | Fever | Rigors | Rash | Blood Pressure | Additional Features | Labs | Treatment | Prevention | Mechanism/
Examples |
---|---|---|---|---|---|---|---|---|---|---|
Anaphylactic Reaction |
|
- | - | - |
|
|
|
|
|
IgA deficiency |
Bacterial Infection |
|
++ | + | +/- |
|
|
|
|
|
+/- |
Acute Hemolytic Reaction |
|
+ | + | +/- |
|
|
|
|
|
ABO incompatibility |
Febrile Non-hemolytic Transfusion Reaction |
|
+, with chills | + | - |
|
|
|
|
|
Cytokine in storage |
Transfusion-related acute lung injury (TRALI) | within 6 hours | +/- | +/- | - |
|
|
|
|
|
Donor anti-leukocyte antibodies |
Transfusion-associated circulatory overload (TACO) | usually over hours | - | - | - |
|
|
|
|
|
+++ |
Transfusion-related acute lung injury (TRALI) can be differentiated from Transfusion associated circulatory overload (TACO) as followed,
Parameters | Transfusion-related acute lung injury (TRALI) | Transfusion-associated circulatory overload (TACO) |
---|---|---|
Fever | +/- | - |
Blood pressure | hypotension | hypertension |
Respiratory Distress | + | + |
JVP | non-distended | distended |
Respiratory auscultation | Rales | Rales + S3 heart sounds may be present |
CXR | bilateral pulmonary infiltrates | bilateral pulmonary infiltrates |
Fluid balance | neutral | positive |
Diuretics | responsive only when there is fluid overload | Improvement with diuretics |
Ejection fraction | normal | decrease |
BNP | <250 pg/mL | >1200 pg/mL |
PCWP | <18 mm Hg | >18 mm Hg |
WBC | unchanged | transient decrease |
See also
External links
- ICD-10 Chapter T: World Health Organisation classification - Complications following infusion, transfusion and therapeutic injection